Sign in
Taking peopleNo phase

Staphylokinase clot-dissolving medicine for massive pulmonary embolism in everyday care

Observes how safe and effective non-immunogenic staphylokinase is in adults with massive pulmonary embolism.

Key facts

Who runs it
Supergene, LLC
Where
Russia14 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Post-registration Trial of the Non-immunogenic Staphylokinase in Massive Pulmonary Embolism
Status
Recruiting
People taking part
20,000 people, planned
Started
1 Jun 2025
Expected to end
31 Dec 2027
Type of study
Observational
Treatments tested
  • Non-immunogenic staphylokinasenon-immunogenic staphylokinase 15 mg as a single intravenous bolus Other Names: Fortelyzin®
Record updated
6 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with massive pulmonary embolism (a large blood clot in the lungs) who get clot-dissolving treatment with non-immunogenic staphylokinase in routine care.

Age
18 years and older
Sex
Men and women
Disease stage
Massive pulmonary embolism confirmed by computer tomography (CT scan). There must be at least one sign of strain or poor function of the right heart chamber, plus ongoing low blood pressure or shock. Symptoms started no more than 14 days ago.
Earlier treatment
People must get clot-dissolving treatment with non-immunogenic staphylokinase, 15 mg as a single injection into a vein.

Main reasons for not taking part

  • High risk of bleeding, for example heavy bleeding now or within the previous 6 months, or bleeding inside the skull now or in the past
  • Stroke caused by bleeding within the last 6 months, or major surgery or major injury within the previous 4 weeks
  • Severe liver disease, stomach or duodenal ulcer within the last 3 months, or acute pancreatitis
  • Pregnancy or breastfeeding
  • Known allergy to non-immunogenic recombinant staphylokinase

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Men and women aged 18 years and older
  • Verified diagnosis of massive pulmonary embolism (using computer tomography)
  • Signs of overload / dysfunction of the right ventricle (at least one) in combination with persistent arterial hypotension or shock
  • The time from the symptoms onset is no more than 14 days
  • Thrombolysis with the non-immunogenic staphylokinase, 15 mg as a single intravenous bolus

Who cannot take part

  • Increased risk of bleeding:; extensive bleeding at present or within the previous 6 months; intracranial (including subarachnoid) hemorrhage at present or in history; hemorrhagic stroke within the last 6 months; a history of diseases of the central nervous system (including neoplasms, aneurysms); intracranial or spinal surgical interventions within the last 2 months; major surgery or major trauma within the previous 4 weeks; recent puncture of an incompressible blood vessel (eg, subclavian or jugular vein); severe liver disease, including liver failure, cirrhosis, portal hypertension (including esophageal varices) and active hepatitis; confirmed gastric or duodenal ulcer within the last 3 months; neoplasm with an increased risk of bleeding; simultaneous administration of Dabigatran without prior administration of idarucizumab; arterial aneurysms, developmental defects of arteries / veins; acute pancreatitis; bacterial endocarditis, pericarditis; suspicion of aortic dissecting aneurysm; any other conditions, in the opinion of the investigator, associated with a high risk of bleeding
  • Known hypersensitivity to the non-immunogenic recombinant staphylokinase
  • Lactation, pregnancy

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of FORPE Registry is to study the safety and efficacy of the non-immunogenic staphylokinase in patients with massive pulmonary embolism in routine clinical practice.

The group in the trial

  • Non-immunogenic staphylokinase

    Drug: non-immunogenic staphylokinase 15 mg as a single intravenous bolus Other Names: Fortelyzin®

    Treatment: Non-immunogenic staphylokinasenon-immunogenic staphylokinase 15 mg as a single intravenous bolus Other Names: Fortelyzin®

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
An Open, Prospective, Non-interventional, Multicentre, Controlled Study of Safety and Efficacy of the Thrombolysis With the Non-immunogenic Staphylokinase in Patients With Massive Pulmonary Embolism (FORPE Registry)
Plain-language title
Staphylokinase clot-dissolving medicine for massive pulmonary embolism in everyday careGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
6 July 2026